143 related articles for article (PubMed ID: 9486923)
1. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin.
Schlegel PG; Haber HP; Beck J; Krümpelmann S; Handgretinger R; Bader P; Bierings M; Niethammer D; Klingebiel T
Ann Hematol; 1998 Jan; 76(1):37-41. PubMed ID: 9486923
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
[TBL] [Abstract][Full Text] [Related]
3. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of low-dose heparin and prostaglandin E1 in the prevention of hepatic veno-occlusive disease after allogenic hematopoietic stem cell transplantation in children with beta-thalassemia major].
Sun X; Hao WG; Liu S; Xia T; Liao C
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):343-6. PubMed ID: 17706036
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
[TBL] [Abstract][Full Text] [Related]
6. Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation.
Park JE; Choi YH; Cheon JE; Kim WS; Kim IO; Ryu YJ; Kim YJ; Hong CR; Kang HJ
Eur Radiol; 2018 Jun; 28(6):2291-2298. PubMed ID: 29294155
[TBL] [Abstract][Full Text] [Related]
7. [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
Chen J; Zhu KE; Zhang T; Zhong J; Chen ST; Zeng HL
Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):140-2. PubMed ID: 17445443
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation].
Inukai T; Sugita K; Goi K; Akahane K; Hirose K; Nemoto A; Takahashi K; Sato H; Uno K; Furuichi Y; Nakamura M; Miyamoto N; Yamakawa N; Shiraishi K; Kojika S; Tezuka T; Iijima K; Nakazawa S
Rinsho Ketsueki; 2004 Apr; 45(4):297-303. PubMed ID: 15168445
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
Bone Marrow Transplant; 2021 Jul; 56(7):1603-1613. PubMed ID: 33526915
[TBL] [Abstract][Full Text] [Related]
10. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
Sonneveld P; Laméris JS; Cornelissen J; Ogilvie A; Löwenberg B
Bone Marrow Transplant; 1998 Apr; 21(7):731-4. PubMed ID: 9578316
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
[TBL] [Abstract][Full Text] [Related]
12. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
[TBL] [Abstract][Full Text] [Related]
13. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
Lee SH; Yoo KH; Sung KW; Koo HH; Kwon YJ; Kwon MM; Park HJ; Park BK; Kim YY; Park JA; Im HJ; Seo JJ; Kang HJ; Shin HY; Ahn HS
Bone Marrow Transplant; 2010 Aug; 45(8):1287-93. PubMed ID: 20010866
[TBL] [Abstract][Full Text] [Related]
14. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
[TBL] [Abstract][Full Text] [Related]
15. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation.
Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Esperou H; Lehn P; Faure P; Drouet L
Br J Haematol; 1990 Mar; 74(3):277-81. PubMed ID: 2159315
[TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis of hepatic veno-occlusive disease by low-molecular-weight heparin and lipo- prostaglandin E1 after allogeneic peripheral blood stem cell transplantation].
Song CY; Li YH; Guo KY; Wu BY
Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):494, 497. PubMed ID: 12754143
[TBL] [Abstract][Full Text] [Related]
17. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
Dong M; Lin Q; Wu XY
Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
[TBL] [Abstract][Full Text] [Related]
18. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
[TBL] [Abstract][Full Text] [Related]
19. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?
Szmit Z; Gorczyńska E; Mielcarek-Siedziuk M; Ussowicz M; Owoc-Lempach J; Kałwak K
Adv Clin Exp Med; 2020 Mar; 29(3):339-344. PubMed ID: 32207590
[TBL] [Abstract][Full Text] [Related]
20. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
